Hiroyuki Arai

Hiroyuki Arai

Auto-generated profile, based on publicly available information

Hiroyuki Arai

Department of Nephrology, Kyoto University Graduate School of Medicine, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Kidney360
Verified
Journal Article
Open access
Miguel Bigotte VieiraMiguel Bigotte Vieira
Miguel Bigotte Vieira
HAHiroyuki Arai
Hiroyuki Arai
CNCarla Nicolau
Carla Nicolau
NMNaoka Murakami
Naoka Murakami
As the population ages and post-transplant survival improves, pretransplant and post-transplant malignancy are becoming increasingly common. In addition, rapid advances in cancer therapies and improving outcomes prompt us to rethink pretransplant cancer-free wait time and screening strategies. Although kidney transplant recipients (KTRs) are at higher risk of developing cancer, epidemiological data on how to best screen and treat cancers in KTRs are incomplete. Thus, current recommendations are still largely on the basis of studies in the general population, and their validity in KTRs is uncertain. Kidney transplant candidates without prior cancer should be evaluated for latent malignancies even in the absence of symptoms. Conversely, individuals with a history of malignancy require thorough monitoring to detect potential recurrences or de novo malignancies. When treating KTRs with cancer, reducing immunosuppression can enhance antitumor immunity, yet this also increases the risk of graft rejection. Optimal treatment and immunosuppression management remains undefined. As the emergence of novel cancer therapies adds complexity to this challenge, individualized risk-benefit assessment is crucial. In this review, we discuss up-to-date data on pretransplant screening and cancer-free wait time, as well as post-transplant cancer screening, prevention strategies, and treatment, including novel therapies such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

30 July 2020 in Kidney360
Verified
Journal Article
Open access
PDF file
HAHiroyuki Arai
Hiroyuki Arai
MYMotoko Yanagita
Motoko Yanagita
Renal fibrosis is a major hallmark of CKD, regardless of the underlying etiology. In fibrosis development and progression, myofibroblasts play a pivotal role, producing extracellular matrix and interacting with various resident cells in the kidney. Over the past decade, the origin of myofibroblasts has been thoroughly investigated. Emerging evidence suggests that renal myofibroblasts originate from several cellular sources, including resident fibroblasts, pericytes, and bone marrow–derived cells. The contribution of resident fibroblasts is most crucial, and currently available data strongly suggest the importance of functional heterogeneity and plasticity of fibroblasts in kidney disease progression. Resident fibroblasts acquire distinct phenotypes based on their local microenvironment and exert multifactorial functions. For example, age-dependent alterations of renal fibroblasts make a significant contribution to the formation of tertiary lymphoid tissues, which promote local inflammation after injury in the aged kidney. In conjunction with fibrosis development, dysfunction of resident fibroblasts provokes unique pathologic conditions including renal anemia and peritubular capillary loss, both of which are major complications of CKD. Although renal fibrosis is considered detrimental in general, recent studies suggest it has beneficial roles, such as maintaining functional crosstalk with injured proximal tubular cells and supporting their regeneration. These findings provide novel insight into the mechanisms of renal fibrosis, which could be regarded as an adaptive process of kidney injury and repair. Precise understanding of the functional heterogeneity of resident fibroblasts and myofibroblasts has the potential to facilitate the development of novel therapeutics against kidney diseases. In this review, we describe the current perspective on the origin of myofibroblasts and fibroblast heterogeneity, with special emphasis on the dual aspects of renal fibrosis, both beneficial and detrimental, in CKD progression.

15 May 2007 in Respiration
Verified
Journal Article
Closed access
PDF file
SESatoru Ebihara
Satoru Ebihara
TETakae Ebihara
Takae Ebihara
SYShinsuke Yamanda
Shinsuke Yamanda
Masanori AsadaMasanori Asada
Masanori Asada
HAHiroyuki Arai
Hiroyuki Arai

8 August 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
HAHiroyuki Arai
Hiroyuki Arai
Yuki SugiuraYuki Sugiura
Yuki Sugiura
SYShinya Yamamoto
Shinya Yamamoto
TYTakahisa Yoshikawa
Takahisa Yoshikawa
YMYuta Matsuoka
Yuta Matsuoka
MYMotoko Yanagita
Motoko Yanagita
Key Points: Glutathione accumulated in tertiary lymphoid structures (TLS), where dendritic cells and fibroblasts specifically expressed cystine/glutamate transporter. Pharmacologic inhibition of the cystine/glutamate transporter prevented the formation of TLS. Urinary glutathione concentrations efficiently detected the presence of TLS in the kidney in mice and humans. Background: Tertiary lymphoid structure (TLS), an ectopic lymphoid tissue induced under chronic inflammation, develops in various kidney diseases and is associated with poor prognosis. The immune system requires metabolic resources to support immune function and lymphocyte proliferation. Hence, dramatic metabolic alterations presumably occur during the formation of TLS. However, it remains unclear whether metabolic remodeling occurs during this formation and its underlying mechanism. Methods: In a murine model of TLS in the kidney, we used imaging mass spectrometry and metabolome analysis to investigate the metabolic pathway that characterizes TLS. We also performed in situ hybridization with immunofluorescence and pharmacologic inhibition to explore the expression and function of the key molecules governing the pivotal metabolic pathway. We analyzed urine samples from mice and humans to explore the metabolites estimating the presence of TLS in the kidney. Results: Significant glutathione accumulation and depletion of cysteine, which is essential for glutathione synthesis, was observed specifically within TLS. The kidneys with TLS exhibited higher glutathione concentrations than healthy kidneys. TLS also showed significant accumulation of 4-hydroxynonenal and 8-hydroxy-2′ -deoxyguanosine, markers of oxidative stress. Dendritic cells and fibroblasts within TLS expressed the cystine/glutamate transporter, which regulates glutathione synthesis, and supplied synthesized glutathione to lymphocytes, which lacked its expression. Pharmacologic inhibition of the cystine/glutamate transporter prevented the formation of TLS in the kidney. Furthermore, enhanced glutathione synthesis within TLS was reflected in elevated urinary glutathione concentrations in both mice and humans, which effectively detected the presence of TLS in the kidney in IgA nephropathy patients. Conclusions: Glutathione significantly accumulated within TLS in the kidney. Inhibition of the cystine/glutamate transporter prevented the formation of TLS. Urinary glutathione served as a biomarker to detect TLS in the kidney.